Inotek Pharmaceuticals

Inotek Pharmaceuticals is developing molecules with novel mechanisms of action to fulfill major unmet medical needs in significant diseases of the eye. Complete loss of vision or vision impairment currently affects 3.3 million people over the age of 40 in the United States, with the most common diseases including age-related macular degeneration (AMD), glaucoma, cataract and diabetic retinopathy. With the continued aging of the population, the National Eye Institute projects that this number will grow to 5.5 million people by the year 2020.

Type
Public
HQ
Lexington, US
Founded
1996
Employees
18 (est)
Inotek Pharmaceuticals was founded in 1996 and is headquartered in Lexington, US

Key People at Inotek Pharmaceuticals

Paul G. Howes

Paul G. Howes

President and CEO

Inotek Pharmaceuticals Locations

Lexington, US

Inotek Pharmaceuticals Metrics

Inotek Pharmaceuticals Summary

Market capitalization

$174 M

Closing share price

$6.7
Inotek Pharmaceuticals's latest market capitalization is $174 M.

Inotek Pharmaceuticals Market Value History

Inotek Pharmaceuticals News

Inotek Pharmaceuticals Company Life